Breakthrough TMVr Therapy for SELECT PATIENTS WITH MITRAL REGURGITATION
MitraClip is the world’s first transcatheter mitral valve repair (TMVr) therapy that delivers a treatment option for patients with mitral regurgitation who would otherwise go untreated.1,2
Over 100,000 patients worldwide* have been treated with MitraClip™ therapy, with over 30,000 patients* followed through multiple studies and registries.
*Data on file at Abbott.
The MitraClip™ TMVr procedure is a minimally invasive catheter-based therapy performed by multidisciplinary Heart Teams.1 Open-heart surgery to repair or replace the mitral valve is generally recommended, but it is not an option for many patients.
TMVr with MitraClip therapy delivers a treatment option for patients who are not good surgical candidates.1,2
MAT-2010221 v1.0 | Item approved for Global OUS use only.
† The testimonial does not provide any indication, guide, warranty or guarantee as to the response patients may have to the treatment or effectiveness of the product or therapy in discussion. Opinions about the treatment discussed can and do vary and are specific to the individual’s experience and might not be representative of others.
- MitraClip G4 Clip Delivery System Instructions for Use.
- Lim DS, Reynolds MR, Feldman T, et al. Improved functional status and quality of life in prohibitive surgical risk patients with degenerative mitral regurgitation after the transcatheter mitral valve repair. J Am Coll Cardiol. 2014;64(2):182-192.